Clinical Trials in Barcelona, Barcelona
3 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Advanced Breast Cancer
MedSIR240 enrolled69 locationsNCT06382948
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NSCLC (Non-small Cell Lung Cancer)
Revolution Medicines, Inc.420 enrolled129 locationsNCT06881784
Recruiting
Not Applicable
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
Breast Cancer
ARTIDIS AG2,706 enrolled5 locationsNCT06085833
Recruiting
Not Applicable
Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
Lung Cancer (Diagnosis)Health Adult SubjectsPatient
Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)1,200 enrolled12 locationsNCT07465848
Recruiting
Phase 2
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Breast Cancer Stage IV
SOLTI Breast Cancer Research Group300 enrolled27 locationsNCT07371585
Recruiting
Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Pathological Response After Neoadjuvant Treatment on NSCLC
Stage IIIA Non-small Cell Lung Cancer
Fundación GECP150 enrolled17 locationsNCT05167487
Recruiting
Phase 2
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
Fundación GECP37 enrolled20 locationsNCT07242547
Recruiting
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Fundación GECP50 enrolled22 locationsNCT06634199
Recruiting
Phase 2
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
Fundación GECP97 enrolled21 locationsNCT07153445
Recruiting
Phase 2
PALACE: Cemiplimab Trial According to ctDNA Levels
Fundación GECP63 enrolled20 locationsNCT06917573
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
SCLC
Zai Lab (Shanghai) Co., Ltd.112 enrolled38 locationsNCT06179069
Recruiting
Phase 1
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer
ORIC Pharmaceuticals250 enrolled27 locationsNCT05413421
Recruiting
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group300 enrolled1 locationNCT06991946
Recruiting
Not Applicable
Multimodal Prehabilitation in Patients with Lung Cancer Undergoing Neoadjuvant Therapy
Hospital Clinic of Barcelona60 enrolled1 locationNCT05636969
Recruiting
The Impact of Radiotherapy on Oligometastatic Cancer
Metastatic Breast CancerMetastatic Lung CancerMetastasis+2 more
Institut Investigacio Sanitaria Pere Virgili2,000 enrolled21 locationsNCT05933876